{"id":"NCT04886596","sponsor":"GlaxoSmithKline","briefTitle":"Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above","officialTitle":"A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-05-25","primaryCompletion":"2022-04-11","completion":"2024-05-31","firstPosted":"2021-05-14","resultsPosted":"2023-08-04","lastUpdate":"2025-07-31"},"enrollment":26675,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Respiratory Syncytial Virus Infections"],"interventions":[{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]},{"type":"BIOLOGICAL","name":"RSVPreF3 OA vaccine","otherNames":[]}],"arms":[{"label":"RSVPreF3 Group","type":"EXPERIMENTAL"},{"label":"Placebo Group","type":"PLACEBO_COMPARATOR"}],"summary":"This study will evaluate the efficacy of the RSVPreF3 OA investigational vaccine in preventing Lower Respiratory Tract Disease (LRTD) caused by RSV in adults â‰¥60 years of age following a single dose of the RSVPreF3 OA vaccine and following annual revaccination doses in Northern Hemisphere (NH) and in Southern Hemisphere (SH). This study will also assess if the vaccine is safe and induces an immune response.","primaryOutcome":{"measure":"Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated Lower Respiratory Tract Disease (LRTD) During the First Season Following a Single Dose of the RSVPreF3 OA Vaccine","timeFrame":"From Day 15 post-vaccination up to end of season 1 in the Northern Hemisphere (NH) [a median of approximately 6.7 months (6.9 months in NH and 3.5 months in Southern Hemisphere [SH])]","effectByArm":[{"arm":"RSVPreF3 Group","deltaMin":7,"sd":null},{"arm":"Placebo Group","deltaMin":40,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"60 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":19},"locations":{"siteCount":277,"countries":["United States","Australia","Belgium","Canada","Estonia","Finland","Germany","Italy","Japan","Mexico","New Zealand","Poland","Russia","South Africa","South Korea","Spain","United Kingdom"]},"refs":{"pmids":["38253338","40245915","38503664","38426479","38314063","37698366","36791160"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1660,"n":12503},"commonTop":["Injection site pain","COVID-19","Headache","Fatigue","Upper respiratory tract infection"]}}